Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020091596 - IGA MEDIATED KILLING OF ABERRANT CELLS BY CD47- SIRPALPHA CHECKPOINT INHIBITION OF NEUTROPHILS

Publication Number WO/2020/091596
Publication Date 07.05.2020
International Application No. PCT/NL2019/050712
International Filing Date 29.10.2019
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/32 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products from oncogenes
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
Applicants
  • UMC UTRECHT HOLDING B.V. [NL]/[NL]
Inventors
  • LEUSEN, Jeanette Henrica Wilhelmina
Agents
  • WITMANS, H.A.
Priority Data
18203183.129.10.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IGA MEDIATED KILLING OF ABERRANT CELLS BY CD47- SIRPALPHA CHECKPOINT INHIBITION OF NEUTROPHILS
(FR) DESTRUCTION À MÉDIATION PAR LES IGA DE CELLULES ABERRANTES PAR INHIBITION DES POINTS DE CONTRÔLE CD47-SIRPALPHA DES NEUTROPHILES
Abstract
(EN)
The invention provides means and methods for stimulating neutrophil- mediated killing of CD47 expressing cells. Methods may include contacting neutrophils with cells that express CD47 and another extracellular membrane- bound antigen in the presence of a first and a second binding moiety, wherein said first binding moiety specifically binds a myeloid Ig A receptor (CD89) and said antigen, and wherein said second binding moiety specifically binds CD47 and/or SIRPα and blocks CD47 mediated signaling of SIRPα in said neutrophil.
(FR)
L'invention concerne des moyens et des procédés pour stimuler la destruction à médiation par les neutrophiles de cellules exprimant CD47. Les procédés peuvent comprendre la mise en contact de neutrophiles avec des cellules qui expriment CD47 et un autre antigène lié à la membrane extracellulaire en présence de première et seconde fractions de liaison, ladite première fraction de liaison se liant spécifiquement à un récepteur pour les IgA de la lignée myéloïde (CD89) et audit antigène, et ladite seconde fraction de liaison se liant spécifiquement à CD47 et/ou à SIRPα et bloquant la signalisation à médiation par CD47 de SIRPα dans lesdits neutrophiles.
Latest bibliographic data on file with the International Bureau